Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,970 matching trials from the local directory fallback.
Filters: Birmingham, Alabama Clear all
Recruiting Phase 2 Interventional

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

NCT06841055
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Docetaxel, Pumitamig
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 6, 2026, 8:07 PM EDT
Recruiting Not applicable Interventional

Prevail Global Study

NCT06535854
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Agent DCB, Prevail DCB
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
1,205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
51
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 15, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional

Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

NCT06943586
View directory record Official record
Conditions
Stroke, Transient Ischemic Attack (TIA)
Interventions
CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy)
Genetic
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 20, 2026, 8:08 PM EDT
Recruiting Phase 2 Interventional

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

NCT05465174
View directory record Official record
Conditions
Craniopharyngioma, Craniopharyngioma, Child, Recurrent Craniopharyngioma
Interventions
Tovorafenib
Drug
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 39 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 1, 2026, 8:14 AM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 14, 2026, 12:54 AM EDT
Recruiting Phase 4 Interventional

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

NCT06829238
View directory record Official record
Conditions
HIV, Immune Dysregulation, Injection Drug Use, Systemic Inflammation
Interventions
Capvaxvie, Jynneos, Metformin, Placebo
Biological · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 12, 2026, 2:09 PM EDT
Recruiting Phase 4 Interventional

The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial

NCT05618353
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Colchicine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
9
States / cities
Birmingham, Alabama • Long Beach, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 15, 2026, 12:53 PM EDT
Recruiting Early Phase 1 Interventional

Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis

NCT03439865
View directory record Official record
Conditions
Chronic Rhinosinusitis (Diagnosis)
Interventions
Ivacaftor, standard of care treatment
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 14, 2026, 12:22 AM EDT
Recruiting Not applicable Interventional

Cognitive Training Intervention and Attitudes Towards Genetics

NCT03094026
View directory record Official record
Conditions
Cognitive Impairment, Hematologic Neoplasms, Hematopoietic Cell Transplant
Interventions
Lumosity, Lumosity (waitlist control)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 14, 2026, 3:12 PM EDT
Recruiting Not applicable Interventional

Comparison of Uncomplicated Candidemia Therapy Duration in Children

NCT05763251
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
therapy duration
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
120 Days and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 1, 2026, 8:00 PM EDT
Recruiting No phase listed Observational

Lupus Landmark Study: A Prospective Registry and Biorepository

NCT05934149
View directory record Official record
Conditions
Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE)
Interventions
Not listed
Lead sponsor
Lupus Research Alliance
Other
Eligibility
18 Years to 110 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 10:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

NCT05559879
View directory record Official record
Conditions
Carcinoma, Endometrial Cancer, Gynecologic Cancer, Uterine Cancer
Interventions
Cabo + Dostarlimab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 10:33 AM EDT
Recruiting Phase 2 Interventional

VENTURI (VENTilation Using Respiratory Imaging)

NCT07282886
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI, Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 12:55 AM EDT
Recruiting No phase listed Observational

Real Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS)

NCT07135284
View directory record Official record
Conditions
Bronchiectasis Adult
Interventions
Airway clearance system
Device
Lead sponsor
Synchrony-Medical, Ltd
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Atlanta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 30, 2026, 1:10 AM EDT
Recruiting Not applicable Interventional

Arterial Stiffness and Blood Pressure

NCT06495710
View directory record Official record
Conditions
Aging, Hypertension, Vascular Stiffness
Interventions
Blood pressure treatment algorithm
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Nashville, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 6:29 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Early Intervention to Promote Cardiovascular Health of Mothers and Children

NCT06272045
View directory record Official record
Conditions
Cardiovascular Health
Interventions
ENRICH, Usual Home Visiting
Behavioral
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older · Female only
Enrollment
6,618 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
9
States / cities
Birmingham, Alabama • San Luis Obispo, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 29, 2026, 4:24 AM EDT
Recruiting Not applicable Interventional

Long COVID Brain Fog: Cognitive Rehabilitation Trial

NCT06095297
View directory record Official record
Conditions
Brain Fog, Cognitive Dysfunction, Cognitive Impairment, Long COVID, Post-Acute COVID-19 Syndrome
Interventions
Follow Up Phone Calls, In-lab Brain Health Training, In-lab Instrumental Activities of Daily Living Training, Peer Mentoring, Processing Speed Training, Reaction Time Training, Trans-auricular Vagus Nerve Stimulation: High Intensity, Trans-auricular Vagus Nerve Stimulation: Low Intensity, Transfer Package, Vocational Rehabilitation
Behavioral · Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 30, 2026, 8:15 PM EDT
Recruiting Phase 1 Interventional

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

NCT06047886
View directory record Official record
Conditions
ALL, AML, CML, Lymphoid Malignancies, Myelodysplastic Syndromes, Primary Myelofibrosis
Interventions
Infusion of CD34 selected hematopoietic stem cells
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
4 Weeks to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 7:40 AM EDT
Recruiting Not applicable Interventional

Constraint-Induced Movement Therapy Plus Sensory Components After Stroke

NCT05515237
View directory record Official record
Conditions
CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis
Interventions
Grade 2-5 CI Therapy + Sensory Components
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 29, 2026, 2:04 AM EDT
Recruiting No phase listed Observational

Valved Graft PMCF Study

NCT04754217
View directory record Official record
Conditions
Aortic Dissection, Aortic Valve Disease, Ascending Aorta Abnormality
Interventions
CAVGJ, VAVGJ
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Asheville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 14, 2026, 3:56 PM EDT
Recruiting Phase 2 Interventional

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

NCT01656603
View directory record Official record
Conditions
Infusion Reactions
Interventions
unlicensed CBU
Biological
Lead sponsor
New York Blood Center
Other
Eligibility
Not listed
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 15, 2026, 2:33 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Aspirin Dose Escalation for the Prevention of Recurrent Preterm Delivery Trial

NCT06980025
View directory record Official record
Conditions
Obstetrical Complications, Preterm Delivery
Interventions
162mg Aspirin, 81mg Aspirin
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
14 Years and older · Female only
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 17, 2026, 9:52 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

NCT06605118
View directory record Official record
Conditions
Cesarean Delivery, Labor and Delivery Complication, Obstetrical Complications
Interventions
Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 16, 2026, 8:58 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

NCT04971720
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Natriuretic Peptides, Nocturnal Blood Pressure, Obesity, Renin-Angiotensin-Aldosterone System
Interventions
Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet, Valsartan 80 mg Oral Tablet
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 17, 2026, 12:29 AM EDT